Semaglutide is a selective GLP-1 receptor monoagonist; tirzepatide is a dual GLP-1R/GIPR co-agonist, giving it an additional incretin signalling pathway not present in semaglutide.
Research reference only — all information on this page summarises peer-reviewed scientific literature and does not constitute medical advice. View full compound profiles: Semaglutide · Tirzepatide
Mechanism Comparison
Semaglutide activates the GLP-1 receptor exclusively, driving glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central satiety signalling. Tirzepatide adds GIPR agonism, which amplifies insulin secretion through a cAMP pathway distinct from GLP-1R and modulates adipose tissue lipid handling. The dual-receptor engagement is the mechanistic basis for tirzepatide's greater magnitude of weight reduction in head-to-head research (SURPASS-2).
Side-by-Side Attributes
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor targets | GLP-1R (monoagonist) | GLP-1R + GIPR (dual agonist) |
| Structural class | C18 fatty diacid–acylated GLP-1 analogue | C20 fatty diacid–acylated dual agonist peptide |
| Half-life (approx.) | ~165–184 hours | ~118–171 hours |
| Dosing route in trials | Subcutaneous, once weekly | Subcutaneous, once weekly |
| Phase 3 weight reduction | ~15% at 68 weeks (STEP 1) | ~20–22% at 72 weeks (SURMOUNT-1) |
| Head-to-head comparison | SURPASS-2 (1.0 mg) | SURPASS-2 (5–15 mg; superior vs sema 1.0 mg) |
| FDA regulatory status | Approved — T2D (Ozempic) & Obesity (Wegovy) | Approved — T2D (Mounjaro) & Obesity (Zepbound) |
| 503A compounding status | Component of FDA Drug (restricted) | Component of FDA Drug (restricted) |
| Primary research utility | GLP-1R pharmacology, incretin biology, CV & neuro research | Dual-receptor incretin signalling, adipose GIPR biology |
Key Research Points
- 1Semaglutide provides a "clean" GLP-1R signal useful for attributing experimental effects specifically to GLP-1R agonism — making it the reference compound in GLP-1R neuroprotection and cardiovascular studies.
- 2Tirzepatide's GIPR co-agonism is the focus of adipose tissue biology research; GIPR is expressed in adipocytes, modulating fatty acid uptake and lipid storage independently of GLP-1R.
- 3SURPASS-2 (N Engl J Med, 2021) — the only direct head-to-head Phase 3 trial — showed tirzepatide (5–15 mg) produced significantly greater HbA1c and body-weight reductions than semaglutide 1.0 mg at 40 weeks.
- 4Both compounds share similar GI adverse-event profiles (nausea, diarrhea) in research populations; preclinical data suggest GIPR co-agonism may partially attenuate GLP-1R-mediated emesis, an active area of investigation.
- 5Both are now FDA-approved drugs under active shortage-resolution enforcement; 503A compounding restrictions apply to both as of 2025–2026.
Frequently Asked Questions
What is the key mechanistic difference between semaglutide and tirzepatide?
Semaglutide is a selective GLP-1 receptor agonist that activates only the GLP-1R, driving glucose-dependent insulin secretion, glucagon suppression, and satiety signalling. Tirzepatide is a dual GLP-1R/GIPR co-agonist: it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide receptor (GIPR), providing an additional incretin signalling pathway that amplifies insulin secretion and modulates adipose tissue lipid handling. This dual-receptor pharmacology is the mechanistic basis for tirzepatide's greater weight-reduction magnitude in head-to-head research.
What did the SURPASS-2 head-to-head trial show comparing tirzepatide to semaglutide?
SURPASS-2 (Frias et al., N Engl J Med, 2021) compared tirzepatide 5/10/15 mg weekly to semaglutide 1.0 mg weekly in adults with type 2 diabetes on metformin over 40 weeks. All three tirzepatide doses produced significantly greater HbA1c reductions (−2.01%, −2.24%, −2.30% vs −1.86%) and body weight reductions (−7.6 kg, −9.3 kg, −11.2 kg vs −5.7 kg) than semaglutide 1.0 mg. Note that the semaglutide comparator was the diabetes dose, not the higher 2.4 mg obesity formulation.
In what research contexts would semaglutide be preferred over tirzepatide?
Semaglutide is preferred when the experimental question requires isolating GLP-1 receptor activity specifically — for example, in GLP-1R neuroprotection studies, brainstem respiratory physiology (GLP-1R expression in nucleus tractus solitarius), cardiovascular GLP-1R signalling research, or any protocol where GIPR co-agonism would confound results. Its monoagonist profile allows researchers to attribute observed effects cleanly to GLP-1R activation. Tirzepatide is appropriate when the question concerns GIPR/GLP-1R interaction or comparative multi-receptor pharmacology.
Deep Dive
For extended mechanism analysis, trial data, and regulatory context, see the full research article:
How Tirzepatide Differs from Semaglutide: Dual Agonist Mechanism →Full compound profile
Semaglutide
Full compound profile
Tirzepatide